To evaluate the effect of anti-diabetic drug( Metformin) when using locally for the treatment of gum disease
Phase 2
Completed
- Registration Number
- CTRI/2022/04/042317
- Lead Sponsor
- DAKAVARAM SOUNDARYA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Systemically healthy subjects.
Sites with probing depth (PD) = 5mm.
Clinical Attachment Level (CAL) = 4mm.
Exclusion Criteria
Patients with any known systemic disease.
Known or suspected allergy to the MF/ biguanide group.
Patients on systemic MF or other anti-diabetic therapy.
Patients with aggressive periodontitis.
Use of tobacco in any form.
Alcoholism
Immunocompromised patients.
Pregnant or lactating females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method plaque scores, clinical attachment level, periodontal probing depth, bleeding on probingTimepoint: Baseline, 3 months
- Secondary Outcome Measures
Name Time Method colony forming unit assesment of subgingival microbiotaTimepoint: baseline, 3months <br/ ><br>